DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

September 11, 2014

Primary Completion Date

March 15, 2018

Study Completion Date

March 15, 2018

Conditions
Glioblastoma or Gliosarcoma
Interventions
DRUG

Single intratumoral injection of DNX-2401

"In the randomized group, following brain tumor biopsy and histological confirmation of recurrent glioblastoma/gliosarcoma, a single injection of DNX-2401 was administered directly into the brain tumor with or without subsequent interferon gamma (IFN-γ)~No additional subjects will be randomized. A single intratumoral dose of DNX-2401 will be delivered by cannula."

DRUG

Interferon-gamma

In the randomized group, a single injection of DNX-2401 was followed by interferon gamma (IFN-γ). No additional subjects will be randomized or receive IFN-γ following DNX-2401

Trial Locations (4)

33612

Moffitt Cancer Center, Tampa

43210

The Ohio State University, Columbus

75246

Baylor University: Charles A. Sammons Cancer Center, Dallas

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

DNAtrix, Inc.

INDUSTRY

NCT02197169 - DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors | Biotech Hunter | Biotech Hunter